Last reviewed · How we verify
S (+) Ketamine
S(+) ketamine is an NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset anesthetic and analgesic effects.
S(+) ketamine is an NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset anesthetic and analgesic effects. Used for Anesthesia induction and maintenance, Acute pain management, Treatment-resistant depression (emerging indication).
At a glance
| Generic name | S (+) Ketamine |
|---|---|
| Sponsor | Asker & Baerum Hospital |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Pain Management, Psychiatry |
| Phase | FDA-approved |
Mechanism of action
S(+) ketamine, the active enantiomer of ketamine, preferentially antagonizes N-methyl-D-aspartate (NMDA) receptors on glutamatergic neurons. This blockade interrupts excitatory neurotransmission and produces dissociative anesthesia, analgesia, and sedation. The S(+) enantiomer is approximately 3-4 times more potent than the racemic mixture and has a faster onset and shorter duration of action.
Approved indications
- Anesthesia induction and maintenance
- Acute pain management
- Treatment-resistant depression (emerging indication)
Common side effects
- Dissociation
- Dizziness
- Nausea
- Increased blood pressure
- Tachycardia
- Hallucinations
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S (+) Ketamine CI brief — competitive landscape report
- S (+) Ketamine updates RSS · CI watch RSS
- Asker & Baerum Hospital portfolio CI